Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple intraportal liver cell applications in acute liver failure
2005-000837-39Phase 2Terminated
- Sponsor
- Cytonet
- Start
- Jan 2007
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human heterologous liver cells in fulminant hepatitis (2 arms), sponsored by Cytonet. Primary endpoint: 8-week survival after randomization. Started Jan 2007; status: terminated.
02
Drugs
human heterologous liver cells
03
Conditions
fulminant hepatitis
Beyond the preview
Go deeper on 2005-000837-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000837-39.